Cargando…

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias

Background: Alzheimer’s disease dementia (ADD) may manifest with atypical phenotypes, resembling behavioral variant frontotemporal dementia (bvFTD) and corticobasal syndrome (CBS), phenotypes which typically have an underlying frontotemporal lobar degeneration with tau proteinopathy (FTLD-tau), such...

Descripción completa

Detalles Bibliográficos
Autores principales:	Constantinides, Vasilios C., Paraskevas, George P., Boufidou, Fotini, Bourbouli, Mara, Pyrgelis, Efstratios-Stylianos, Stefanis, Leonidas, Kapaki, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955886/ https://www.ncbi.nlm.nih.gov/pubmed/36832271 http://dx.doi.org/10.3390/diagnostics13040783

Ejemplares similares

Application of the AT(N) and Other CSF Classification Systems in Behavioral Variant Frontotemporal Dementia
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal Dementia
por: Kapaki, Elisabeth, et al.
Publicado: (2022)

Alzheimer’s Disease CSF Biomarkers as Possible Indicators of Tap-Test Response in Idiopathic Normal Pressure Hydrocephalus
por: Pyrgelis, Efstratios-Stylianos, et al.
Publicado: (2023)

Callosal Angle Sub-Score of the Radscale in Patients with Idiopathic Normal Pressure Hydrocephalus Is Associated with Positive Tap Test Response
por: Pyrgelis, Efstratios-Stylianos, et al.
Publicado: (2022)

Recognizing Atypical Presentations of Alzheimer’s Disease: The Importance of CSF Biomarkers in Clinical Practice
por: Paraskevas, George P., et al.
Publicado: (2022)

Cerebrospinal Fluid Biomarkers in iNPH: A Narrative Review
por: Pyrgelis, Efstratios-Stylianos, et al.
Publicado: (2022)

Mixed Small Vessel Disease in a Patient with Dementia with Lewy Bodies
por: Paraskevas, George P., et al.
Publicado: (2019)

Imaging Markers for Normal Pressure Hydrocephalus: An Overview
por: Pyrgelis, Efstratios-Stylianos, et al.
Publicado: (2023)

Neuronal and Neuroaxonal Damage Cerebrospinal Fluid Biomarkers in Autoimmune Encephalitis Associated or Not with the Presence of Tumor
por: Vakrakou, Aigli G., et al.
Publicado: (2022)

Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias
por: Baiardi, Simone, et al.
Publicado: (2018)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
por: Wisch, Julie K., et al.
Publicado: (2023)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
por: Suire, Caitlin N., et al.
Publicado: (2020)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

Genotyping and Plasma/Cerebrospinal Fluid Profiling of a Cohort of Frontotemporal Dementia–Amyotrophic Lateral Sclerosis Patients
por: Bourbouli, Mara, et al.
Publicado: (2021)

Diagnostic Utility of CSF Tau and Aβ (42) in Dementia: A Meta-Analysis
por: Agarwal, Rachna, et al.
Publicado: (2011)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
por: Oh, Esther S., et al.
Publicado: (2018)

Corticobasal degeneration and corticobasal syndrome: A review
por: Constantinides, Vasilios C., et al.
Publicado: (2019)

Novel PANK2 mutation in the first Greek compound heterozygote patient with pantothenate-kinase-associated neurodegeneration
por: Paraskevas, George P, et al.
Publicado: (2017)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases
por: Kapaki, Elisabeth, et al.
Publicado: (2022)

Correction: Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
Publicado: (2018)

Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40
por: Hu, Xiaoyan, et al.
Publicado: (2014)

Different Aggregation Pathways and Structures for Aβ40 and Aβ42 Peptides
por: Wang, Li, et al.
Publicado: (2021)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
por: Wilczyńska, Karolina, et al.
Publicado: (2020)

Lower CSF Amyloid-Beta(1–42) Predicts a Higher Mortality Rate in Frontotemporal Dementia
por: Vieira, Daniela, et al.
Publicado: (2019)

Aggregation States of Aβ(1–40), Aβ(1–42) and Aβp(3–42) Amyloid Beta Peptides: A SANS Study
por: Festa, Giulia, et al.
Publicado: (2019)

Reduced CSF turnover and decreased ventricular Aβ42 levels are related
por: Serot, Jean-Marie, et al.
Publicado: (2011)

Prognostic Role of CSF β-amyloid 1–42/1–40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis
por: Colletti, Tiziana, et al.
Publicado: (2021)

Amyloid β-peptides 1–40 and 1–42 form oligomers with mixed β-sheets
por: Baldassarre, Maurizio, et al.
Publicado: (2017)

Impact of Aβ40 and Aβ42 Fibrils on the Transcriptome of Primary Astrocytes and Microglia
por: Zhu, Xiaoyue, et al.
Publicado: (2022)

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology
por: Michno, Wojciech, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vpg05jnvjfcb4kp7i94aq3fg9m